Epigenetic inactivation of RUNX3 in colorectal cancer

Eung Jin Shin1,*, Han Jo Kim2,*, Myoung Won Son1, Tae Sung Ahn1, Hyun Yong Lee1, Dae Ro Lim1, Sang Byung Bae2, Seob Jeon3, Hyungjoo Kim4, Dongjun Jeong4, Moon Soo Lee1, Dong-Sun Kim5, Jeong Se Noh6, Moo-Jun Baek1

1Department of Surgery, Soonchunhyang University College of Medicine, Cheonan, Korea
2Department of Hematology and Oncology, Soonchunhyang University College of Medicine, Cheonan, Korea
3Department of Obstetrics and Gynecology, Soonchunhyang University College of Medicine, Cheonan, Korea
4Medical Science Research Institute, Soonchunhyang University, Cheonan, Korea
5Department of Anatomy, Kyungpook National University School of Medicine, Daegu, Korea
6Soonchunhyang University College of Medicine, Cheonan, Korea

INTRODUCTION

Colorectal cancer (CRC) is one of the most frequently diagnosed cancer types, and it accounts for a high annual mortality rate worldwide [1]. Although the relative 5-year survival rate of CRC has increased globally, it is only about 65%–70%. Until now, pathological staging has been the most accurate predictor of CRC prognosis. Therefore, novel prognostic markers for CRC are needed to allow for accurate predictions. Runt-related transcription factors (RUNXs) are a family of proteins that are important in the normal development and differentiation of cells. In mammals, the RUNX family consists of 3 gene groups, namely RUNX1, RUNX2, and RUNX3 [2-5]. The gene RUNX1 is located on human chromosome 21q22.12, and it is involved in hematopoiesis and the growth of megakaryocytes. T cells, and B cells. RUNX2 is located on chromosome 6p21; it is involved

Purpose: Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC.

Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining.

Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363).

Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.

Key Words: Colorectal neoplasms, Prognosis, RUNX3 protein, Methylation, Immunohistochemistry
in bone differentiation and may thus be associated with bone-related diseases [6]. Finally, RUNX3 is located in 1p36 and is thought to be a tumor suppressor gene [6]. Recent studies have shown that it is associated with various malignancies, such as stomach, liver, lung, and esophageal cancers [7-15].

Aberrant signaling through this pathway is thought to promote tumor development in several tissues. Typically, inactivation of RUNX3 originates from allele loss or gene-silencing due to hypermethylation in CpG islands of the promoter region. However, the clinical significance of RUNX3 inactivation remains unclear. In this study, we used tissue microarrays containing primary CRC tissues to investigate the hypermethylation and expression of RUNX3 in relation to tumor features and to patient outcomes.

METHODS

CRC tissue samples

In the current study, we used 62 CRC tissue samples and 10 normal mucosal tissue samples collected from 62 patients who were diagnosed with CRC and underwent surgery at Soonchunhyang University Hospital. CRC and normal mucosal tissue samples were taken from the specimens, and each sample was divided each into 2 parts. One part of the sample was placed in liquid nitrogen immediately, while the other was embedded in a paraffin block after fixation in cold 10% neutral buffered formalin for 24 hours. For the diagnosis of cancer, a 4-μm paraffin section was stained using hematoxylin-eosin dye, and the histopathological findings were interpreted by a pathologist.

DNA extraction and bisulfite modification

To perform methylation-specific polymerase chain reaction (MS-PCR), a G-spin Genomic DNA Extraction Kit (Intron, Seongnam, Korea) was used to extract DNA from the tissue samples according to the manufacturer’s instructions. Approximately 300 ng of DNA was diluted in 30 μL of distilled water, to which 3 μL of 3 M NaOH was added. The mixture was incubated at 75°C for 20 minutes and subsequently cooled on ice. The DNA was then treated with 20 μL of 10 mM hydroquinone (Sigma-Aldrich, St. Louis, MO, USA) and 500 μL of 4.8 M sodium bisulfite (Sigma-Aldrich) and stirred well. This was followed by a 5-hour incubation at 55°C. Modified DNA impurities were removed using a Wizard DNA Clean-Up Kit (Promega, Madison, WI, USA). The mixture was then stored at room temperature using 0.5 M NaOH. Finally, DNA was precipitated using 100% ethanol and subsequently dried. Dried DNA was melted in 20 μL of distilled water prior to use as a template in PCR.

Methylation-specific polymerase chain reaction

Hypermethylation of the RUNX3 promoter was investigated via MS-PCR using methylation-specific primers. The primer sequences used to examine the methylated RUNX3 promoter were 5′-TTA CGA GGG GCG GTG TTA TCA CGC GGG-3′ (sense) and 5′-AAA ACG ACC GAC GCG AAC GCC TCC-3′ (antisense), while those used to examine the unmethylated RUNX3 promoter were 5′-TTA TGA GGG GTG GTG TTA TGT GGG-3′ (sense) and 5′-AAA ACA ACC ACA AAC ACC TCC-3′ (antisense). A series of reactions were performed in 35 cycles following the PCR conditions: 2 minutes at 50°C, heat denaturation reaction for 10 minutes at 95°C, denaturation for 15 seconds at 95°C, annealing for 15 seconds at 55°C, and extension for 30 seconds at 72°C. The PCR products were confirmed using 10% TBE acrylamide gel. Positive controls for these reactions utilized universally methylated DNA (InterGen, Burlington, MA, USA). Distilled water was used instead of the DNA template in the negative control.

RNA extraction and reverse transcriptase-PCR

Total RNA was extracted from tissue samples using the TRizol Reagent (Life Technologies Inc., Grand Island, NY, USA) according to the manufacturer’s instruction. Total extracted mRNA was purified using the RNeasy Mini kit (Qiagen, Hilden, Germany) and treated by RNase-free DNA I to remove genomic DNA contamination. Five hundred ng/μL of mRNA was reverse transcribed using a ReverTraAce qPCR RT kit (Toyobo, Tokyo, Japan) and reverse transcription PCR was performed using the MaxiCor PCR PreMix i-starTag kit (Intron) according to the manufacturer’s instruction. The following primers were used for reverse transcription (RT)-PCR: human RUNX3 sense; 5′-GAG TTT CAC CCT GAC CAT CAC TGT G-3′, antisense; 5′-GCC CAT CAC TGG TCT TGA AGG TTG TG-3′ and human GAPDH sense: 5′-ACG ACT TTG TCA AGC TC-3′, antisense; 5′-TCT TCC TCT TGT GCT TCT GC-3′. PCR products were analyzed and visualized by 2% agarose gel electrophoresis.

Immunohistochemical staining

To examine the correlation between hypermethylation of the RUNX3 promoter and RUNX3 protein expression, immunohistochemical (IHC) staining was performed. To retrieve antigen, sectioned samples on slides were placed in 0.01 M sodium citrate buffer (pH, 6.0) and boiled in a microwave for 20 minutes. Samples were then cooled to room temperature for more than 1 hour and rinsed three times (3 minutes each) in distilled water. To inhibit the intrinsic activity of peroxidase, methanol was used to prepare a 3% hydrogen peroxide solution, and the tissue samples were incubated in this solution at room temperature for 30 minutes. The tissue samples were then rinsed with distilled water 3 times, following which they were washed 3 times with phosphate-buffered saline (PBS; pH, 7.4). The samples were then incubated with the primary antibody (1:100) for 1 hour at room temperature. Again, the...
sample was rinsed with PBS three times (3 minutes each). The tissue samples were incubated with a PicTure-Plus Kit (Zymed Laboratories Inc., South San Francisco, CA, USA) for 30 minutes at room temperature. After the samples were rinsed with PBS three times, diaminobenzidine was added to the samples; following this, they were counterstained with hematoxylin dye and examined using light microscopy.

**IHC analysis**

RUNX3 stained tissue cores were examined by 2 independent pathologists, and a consensus score was determined for each specimen. A positive reaction for the antibody was scored into four categories, as follows: 0 (0%), 1+ (1%–33%), 2+ (34%–66%), and 3+ (67%–100%). RUNX3 expression was defined to be expressed in the nucleus or cytoplasm if the intensity was estimated at ≥2 (Fig. 1).

**Statistical analysis**

The correlations between hypermethylation/expression of RUNX3 and clinicopathologic parameters were evaluated using the chi-square or Fisher exact test. The overall survival was calculated as the first diagnosis of CRC to death from any other cause or until April 2016. Survival curves were estimated using the Kaplan-Meier method. All P-values quoted were 2-sided, and P < 0.05 was considered to indicate a statistically significant difference. All analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

**Patient characteristics**

Between January 2008 and February 2009, 62 patients with a median age of 64 years (range, 31–83 years) were included in the study. There were 37 men (59.7%) and 25 women (40.3%).

**Fig. 1.** Immunohistochemical staining for RUNX3 (×400). (A) RUNX3 was not expressed in normal colonic mucosa tissue. RUNX3 was strongly (3+) (B), moderately (2+) (C), and weakly (1+) (D) expressed in colorectal cancer tissues. RUNX3, runt-related transcription factor 3.
Two patients (3.2%) were in stage IV. The most common histological grade of tumor was moderate differentiation (51 patients, 82.3%). The baseline characteristics are listed in Table 1.

### Prevalence of RUNX3 hypermethylation

MS-PCR was performed in 62 CRC tissue samples and 10 normal colon tissue samples (Fig. 2). Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters, while the remaining 42 (67.7%) showed no methylation. All 10 normal colon tissue samples showed no methylation.

### Relationship between hypermethylation and mRNA expression of RUNX3

To examine the correlation between hypermethylation and mRNA expression of RUNX3, RT-PCR was performed for all CRC tissue samples, as well as the 10 normal colon tissue samples...
The mRNA expression of RUNX3 was observed in all 10 normal colon tissue samples. However, of the 20 samples that showed RUNX3 promoter hypermethylation, 14 (70.0%) exhibited decreased expression of RUNX3 compared to normal colorectal tissue samples, while the remaining 6 samples (30.0%) showed normal RUNX3 expression. In contrast, of the 42 CRC tissue samples that showed no RUNX3 promoter hypermethylation, 27 (64.3%) demonstrated normal mRNA expression and 15 (35.7%) exhibited decreased expression. Hypermethylation of CpG islands of the promoter region of RUNX3 was significantly associated with expression of RUNX3 mRNA (P = 0.011) (Table 1).

**Association between promoter hypermethylation of RUNX3 and clinicopathological parameters**

When the tumors of the 62 patients were divided according to pathological stage classification, stage was not associated with RUNX3 methylation status (P = 0.307). We also found that differentiation of cancer was not correlated with hypermethylated RUNX3 (P = 0.179). However, promoter hypermethylation of RUNX3 was significantly associated with vascular invasion (P = 0.006) and lymphatic invasion (P = 0.002) (Table 1). In contrast, other clinicopathological variables showed no correlation with hypermethylated RUNX3.

**Hypermethylation/expression of RUNX3 and overall survival**

The median follow-up duration of the 62 CRC patients was 81.3 months (range, 8.9–96 months). Eighteen patients died during the follow-up period. All patients died from cancer progression. Compared to unmethylation, hypermethylation of RUNX3 was significantly associated with worse CRC prognosis (P = 0.038, log-rank test) (Fig. 4). Promoter hypermethylation was significantly associated with expression of RUNX3 (P = 0.019). However, RUNX3 expression in patients was not associated with CRC prognosis (P = 0.363, log-rank test) (Fig. 5).

**DISCUSSION**

The molecular mechanisms underlying the malignant transformation of colorectal tissues can be divided into the typical adenoma-carcinoma sequence and the acquired genetic changes due to promoter hypermethylation of tumor suppressor genes [16]. The genes that are associated with the acquired genetic changes include p16 and Rb, which are involved in controlling the cell cycle; E-cadherin and TIMP-3, which are involved in cell attachment; and hMLH1, BRCA1, MGMT, and p14, which are involved in DNA repair. These genes act as etiological factors for cancer when their expression is decreased by the hypermethylation of promoters [17]. The RUNX3 gene encodes a tumor suppressor protein and is located on chromosome 1p36. It plays a role as a regulator of mRNA transcription along with TGF-β and the tumor-suppressing functions of the complex composed of Smad2, Smad4, p300, and RUNX3 must be well harmonized [20].
In stomach cancer tissue, the inactivation of RUNX3 has been reported to occur because of the hypermethylation of CpG islands within the promoter region. A correlation between the malignant transformation of stomach tissue and RUNX3 expression was identified in 8.1% of patients with gastritis, 27.3% of those with gastric adenoma, and 64.0% of those with stomach cancer [9]. These results suggest that malignant transformation of many cell types may be associated with promoter methylation status [9].

In the current study, MS-PCR was performed for the promoter region of RUNX3, which revealed promoter hypermethylation in 32.3% of CRC tissue samples. In normal colon tissue samples, no methylation was detected. These proportions are lower than those reported by Oshimo et al. [8], who observed hypermethylation in 71.0% of stomach cancer tissue samples. In recent years, several follow-up studies have been conducted to examine the hypermethylation of RUNX3 promoter CpG islands.

The correlation between the status of RUNX3 promoter methylation and the expression of mRNA was also assessed, which showed that mRNA was not expressed in 14 of 20 CRC tissue samples (70.0%) with hypermethylated promoter regions, but it was detected in the remaining 6 samples (30.0%). Of the 42 samples that showed no methylation of the RUNX3 promoter, 27 (64.3%) exhibited expression of RUNX3 mRNA, while 15 (35.7%) did not (Table 1). Comparing these results to those of prior publications, a smaller proportion of cancer cells showed no mRNA expression. Tumor heterogeneity may be responsible for these findings.

Little is known about the correlations between the clinical characteristics of CRC and hypermethylation of the RUNX3 promoter. Some studies have described the above correlation in patients with stomach cancer or urinary bladder cancer. However, in patients with hepatoma, no statistically significant association has been reported [12,21]. Recent studies have determined that hypermethylation or expression of RUNX3 is highly associated with higher pathological staging and poor prognosis in various tumors, including CRC. However, these results have not been consistent. In addition, only 2 studies estimated the relationship between overall survival and RUNX3 hypermethylation/expression in CRC [22]. Ogino et al. [23] reported that CRC patients with RUNX3 hypermethylation had a poorer 1-year survival than those without RUNX3 hypermethylation (P < 0.001). However, the follow-up duration was only 1 year. In this study, we found that hypermethylation of RUNX3 was significantly associated with worse prognosis of CRC after 8 years of follow-up (P = 0.038).

Contrary to our expectation, the present data showed that RUNX3 expression was not associated with CRC prognosis (P = 0.363). Soong et al. [24] observed that RUNX3 expression was associated with better survival than no RUNX3 expression (P = 0.025). Interestingly, in this study, cytoplasmic expression of RUNX3 (only 9% of the study) was associated with worse prognosis. However, patients with no expression of RUNX3 showed similar prognoses to those with RUNX3 nuclear expression. To accurately determine the association of prognosis with RUNX3 expression, we need to analyse the RUNX3 expression in the nucleus or cytoplasm in further studies. The associations between RUNX3 hypermethylation and the clinicopathologic features of CRC are shown in Table 1. No significant association was seen with age, sex, histological grade, or stage. However, hypermethylation of RUNX3 was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion.

The limitations of the present study include its retrospective design and relatively small sample size. It could have been affected by potential selection bias. In conclusion, the major finding of this study was that hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC cases. However, further large-scale studies are warranted to determine the clinical significance, including prognosis, of RUNX3 hypermethylation/ expression in CRC.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI15C0031). This work was also supported by the Soonchunhyang University Research Fund.

REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue Ki, Chi XZ et al. Causal relationship between the loss of RUNX3 expression...
and gastric cancer. Cell 2002;109:113-24.
3. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004;23:6736-42.
4. Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004;112:754-9.
5. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene 2004;23:4336-40.
6. Ozaki T, Nakagawara A, Nagase H. RUNX family participates in the regulation of p53-dependent DNA damage response. Int J Genomics 2013;2013:271347.
7. Torquati A, O’rear L, Longobardi L, Spagnoli A, Richards WO, Daniel Beauchamp R. RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 2004;136:310-6.
8. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, et al. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004;71:137-43.
9. Osaki M, Moriyama M, Adachi K, Nakada C, Takeda A, Inoue Y, et al. Expression of RUNX3 protein in human gastric mucosa, intestinal metaplasia and carcinoma. Eur J Clin Invest 2004;34:605-12.
10. Nakase Y, Sakakura C, Miyagawa K, Kin S, Fukuda K, Yanagisawa A, et al. Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography. Br J Cancer 2005;92:562-9.
11. Levanon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep 2003;4:560-4.
12. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 2004;10:376-80.
13. Guo C, Ding J, Yao L, Sun L, Lin T, Song Y, et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer 2005;116:155-60.
14. Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004;314:223-8.
15. Kato N, Tamura G, Fukase M, Shibuya H, Motoyama T. Hypermethylation of the RUNX3 gene promoter in testicular yolk sac tumor of infants. Am J Pathol 2003;163:387-91.
16. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
17. Nishio M, Sakakura C, Nagata T, Komiya S, Miyashita A, Hamada T, et al. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res 2010;30:2673-82.
18. Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 2003;13:43-7.
19. Fukushige S, Horii A. DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med 2013;229:173-85.
20. Chi XZ, Yang JQ, Lee KY, Ito K, Sakakura C, Li QL, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor (beta)-activated SMAD. Mol Cell Biol 2005;25:8097-107.
21. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, et al. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med 2005;37:276-81.
22. Mu WP, Wang J, Niu Q, Shi N, Lian HF. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis. Oncol Targets Ther 2014;7:1237-45.
23. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007;450:529-37.
24. Soong R, Shah N, Peh BK, Chong PY, Ng SS, Zeps N, et al. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer 2009;100:676-9.